Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.

Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG.

J Clin Oncol. 2009 Mar 1;27(7):1116-21. doi: 10.1200/JCO.2008.19.6857.


Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG.

J Clin Oncol. 2012 Dec 10;30(35):4344-51. doi: 10.1200/JCO.2012.43.8085.


Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C.

JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914.


Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.

Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):638-45. doi: 10.1016/j.ijrobp.2013.07.035.


Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.

Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH.

Dis Colon Rectum. 2005 Sep;48(9):1742-51.


Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.

Doyen J, Benezery K, Follana P, Ortholan C, Gérard JP, Hannoun-Levi JM, Gal J, Francois E.

Dis Colon Rectum. 2013 Oct;56(10):1125-33. doi: 10.1097/DCR.0b013e3182a226bd.


[Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].

Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, Parc R, Huang R, Qu SH, Pène F, Schlienger M.

Cancer Radiother. 2003 Aug;7(4):237-53. French.


Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.

Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N.

Cancer. 2003 Mar 1;97(5):1195-202.


[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].

Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M.

Cancer Radiother. 2006 Dec;10(8):572-82. French.


Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results.

Olivatto LO, Cabral V, Rosa A, Bezerra M, Santarem E, Fassizoli A, Castro L, Simões JH, Small IA, Ferreira CG.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):490-5. doi: 10.1016/j.ijrobp.2009.11.057.


Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.

Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D; ACT II Study Group..

Ann Oncol. 2014 Aug;25(8):1616-22. doi: 10.1093/annonc/mdu188.


Review of anal cancer patients at the Ottawa hospital.

Abunassar M, Reinders J, Jonker DJ, Asmis T.

Eur J Surg Oncol. 2015 May;41(5):653-8. doi: 10.1016/j.ejso.2015.02.004.


Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.

Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9. doi: 10.1016/j.ijrobp.2008.10.046.


Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy.

Fraunholz I, Rödel F, Kohler D, Diallo-Georgiopoulou M, Distel L, Falk S, Rödel C.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):901-7. doi: 10.1016/j.ijrobp.2013.03.039.


Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C.

J Clin Oncol. 2010 Dec 1;28(34):5061-6. doi: 10.1200/JCO.2010.29.1351.


Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.

White EC, Goldman K, Aleshin A, Lien WW, Rao AR.

Radiother Oncol. 2015 Nov;117(2):240-5. doi: 10.1016/j.radonc.2015.08.015.


Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.

Wong CS, Tsao MS, Sharma V, Chapman WB, Pintilie M, Cummings BJ.

Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14.


Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.

Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH.

Cancer. 2013 Nov 1;119(21):3769-75. doi: 10.1002/cncr.28296.


Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.

Konski A, Garcia M Jr, John M, Krieg R, Pinover W, Myerson R, Willett C.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8. doi: 10.1016/j.ijrobp.2007.12.027.

Supplemental Content

Support Center